Evaluation of the plasma levels of LncRNAs as biomarker for late-onset Alzheimer’s disease

Backgrounds: Alzheimer’s disease (AD) is a neurodegenerative disorder and one of the leadingcauses of death in old people across the world. Recent studies demonstrated that long noncodingRNAs (LncRNAs) play important roles in AD. These circulating LncRNAs are a novelpromising biomarker in AD as they possess characteristics of stable. This project was aimed atinvestigating the diagnostic and prognostic value of long noncoding RNAs involved in ADpathogenesis.Materials and Methods: Total RNA was isolated from plasma samples. The expression levelsof ۹۰ LncRNAs were estimated using the PCR arrays containing ۹۰ LncRNAs and by real-timeqRT-PCR. Then, by analyzing the preliminary results of profiling, the genes BC۲۰۰, NDM۲۹,NEAT۱, FAS-AS۱ and GAS۵-AS۱ were selected for further studies in all samples. In the nextstep, biomarker potency of each factor was analyzed by ROC Curve analysis. we furtherperformed transcriptome analysis to identified expression patterns of LncRNAs in AD.Results: We found that the NEAT۱ and BC۲۰۰ level in the plasma samples of the AD patientswere significantly up-regulated compared with the control groups (P = ۰.۰۰۲۱, P = ۰.۰۲,respectively). ROC curve analysis showed that NEAT۱ with ۷۲% sensitivity and ۸۴% specificityand BC۲۰۰ with ۵۴% sensitivity and ۹۲% specificity appropriately discriminated AD patientsfrom healthy controls. In addition, negative correlation was between plasma LncRNANEAT۱and BC۲۰۰ levels with age. ۱۳down-regulated and ۳۳ up-regulated LncRNAs wereidentified, compared with normal brain samples as a result of RNAseq.Conclusion: This study elucidates the role of LncRNAs in the pathogenesis of AD and presentsnew LncRNAs that may be exploited as a promising biomarker for early diagnosis of AD.

کلیدواژه ها:

Alzheimer’s disease ، Long non-coding RNA ، Biomarker ، Early diagnosis ، RNAseq